COVID-19: Denmark becomes country first to junk AstraZeneca due to rare blood clot cases
File Image

Copenhagen: Denmark on Wednesday became the first country to stop using AstraZeneca’s Covid-19 vaccine altogether over a potential link to a rare but serious form of a blood clot.

The decision will push back the scheduled conclusion of Denmark’s vaccination scheme to early August from July 25, health authorities said.

But that new timeline assumes it will start using the Johnson & Johnson vaccine, whose rollout in Europe has been delayed over similar clotting concerns and the use of which Denmark has suspended. That shot comprises around a third of the country’s total contracted supply.

Results of investigations into the AstraZeneca-associated blood clots “showed real and serious side effects,” Danish health agency head Soren Brostrom told a news briefing.

“We have therefore chosen to continue the vaccination programme for all target groups without this vaccine," it added.

AstraZeneca said it respected Denmark’s choice and would continue to provide it with data to inform future decisions.

“Implementation and rollout of the vaccine programme is a matter for each country to decide, based on local conditions,” the Anglo-Swedish company said.

The European Union’s drug watchdog said last week it had found a possible link between the AstraZeneca vaccine and cerebral venous sinus thrombosis (CVST), a brain blood clot.

It said the risk of dying from Covid-19 was much greater than the risk of mortality from rare side effects but left it to individual states to make their own risk assessments and decide how to administer the vaccine.

Soren Brostrom said joint studies based on Danish and Norwegian health data estimated that one in 40,000 people vaccinated with the AstraZeneca shot could expect to experience this serious complication, with nothing conclusive related to age or gender.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal